Moolec Science (NASDAQ:MLEC) (NASDAQ:MLEC) is a clinical-stage biotechnology company specializing in the development of synthetic messenger RNA (mRNA) molecules for therapeutic and cosmetic applications. Leveraging proprietary chemistry and formulation techniques, the company designs tailored mRNA constructs that target skin health, tissue regeneration, and localized delivery without the need for viral vectors. Its technology platform aims to unlock the potential of mRNA beyond vaccines by enabling controlled expression of therapeutic proteins and peptides directly within targeted tissues.
The company’s research portfolio includes mRNA-based products for dermatological conditions such as wound healing, anti-aging, and hair regrowth. Moolec Science has advanced several preclinical programs focused on enhancing skin barrier function and promoting tissue repair. In parallel, the firm is exploring innovative bioelectronic approaches that combine synthetic mRNA with electronic interfaces to modulate cellular activity, reflecting its ambition to create next-generation precision therapies.
Founded as a spin-out from leading academic institutions, Moolec Science maintains research laboratories in Tel Aviv and a presence in North America to facilitate collaboration with global partners. Since its inception, the company has attracted support from biotechnology investors and has engaged in strategic alliances for formulation development and clinical translation. Its cross-continental operations enable access to diverse talent pools and regulatory expertise, positioning it for advancement through clinical milestones.
Moolec Science is led by a team of experienced biotech executives and scientific advisors. The company’s founder and chairman, Professor Dan Peer, brings extensive expertise in RNA therapeutics and nanomedicine, while the executive leadership team combines backgrounds in drug development, regulatory affairs, and commercial strategy. Together, they aim to harness the versatility of synthetic mRNA to address unmet medical needs and establish new standards in cosmeceutical and therapeutic innovation.
